At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Cholecystokinin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cholestasis
Most Recent Events
- 17 Oct 1994 No-Development-Reported for Cholestasis in USA (Unknown route)